Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient

Abstract

Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form of uveitis, in her left eye 2 weeks after starting dupilumab treatment, which improved after reducing the dose, without discontinuing dupilumab. The patient also experienced asymptomatic hypereosinophilia, possibly related to dupilumab, which was gradually relieved without discontinuation. With the readers, we share our experience in managing uveitis and hypereosinophilia associated with dupilumab, which may be helpful in managing these conditions and avoiding discontinuation of dupilumab.

Keywords:

• Dupilumab
• uveitis
• hypereosinophilia
• atopic dermatitis
• biologics

Authors’ contribution

TW, DC and YL made the clinical diagnosis, designed the observational study and critically reviewed the article. SZ collected the clinical information, drafted the manuscript and revised the article. ZH, HS and LY performed acquisition of data in literature. LL and JF collected and analyzed the follow-up data. All authors reviewed the manuscript and agreed on all versions of the article.

Ethical approval

This study has been approved by the institutional ethics committee (S-k1773).

Patient consent

Written informed consent for patient information and images to be published was provided by the patient.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author, TW, upon reasonable request.

Additional information

Funding

This work was supported by the National High Level Hospital Clinical Research Funding under Grant 2022-PUMCH-B-092 to TW, the Beijing Natural Science Foundation under Grant Z210017 to TW, and the National High Level Hospital Clinical Research Funding under Grant 2022-PUMCH-A-164 to TW.